Table 2. CIN2+ and CIN3+ prevalence by age group, HIV status and HPV subtype in the cervical screening cohort.
| 30–49 years | ≥50 years | |||||
| Number with HPV type | CIN2+ | CIN3+ | Number with HPV type | CIN2+ | CIN3+ | |
| Women with HIV | ||||||
| Any hrHPV | 558 | 89 (15.9) | 69 (12.4) | 187 | 36 (19.3) | 26 (13.9) |
| HPV 16 | 85 | 19 (22.4) | 16 (18.8) | 31 | 11 (35.5) | 9 (29.0) |
| HPV 18/45 | 115 | 27 (23.5) | 25 (20.9) | 35 | 9 (25.7) | 7 (20.0) |
| HPV 31/33/35/52/58 | 314 | 61 (19.4) | 49 (15.6) | 93 | 21 (22.6) | 16 (17.2) |
| HPV 39/51/56/59/68 | 265 | 36 (13.6) | 24 (9.1) | 91 | 18 (19.8) | 12 (13.2) |
| Coinfection with 16 or 18 | 103 | 28 (27.2) | 25 (24.3) | 35 | 13 (37.1) | 11 (31.4) |
| Any coinfection | 267 | 56 (21.0) | 45 (16.9) | 99 | 26 (26.3) | 20 (20.2) |
| Women without HIV | ||||||
| Any hrHPV | 377 | 50 (13.3) | 31 (8.2) | 134 | 14 (10.4) | 9 (6.7) |
| HPV 16 | 64 | 8 (12.5) | 4 (6.3) | 17 | 2 (11.8) | 1 (5.9) |
| HPV 18/45 | 62 | 7 (11.3) | 6 (9.7) | 27 | 3 (11.1) | 2 (7.4) |
| HPV 31/33/35/52/58 | 176 | 37 (21.0) | 26 (14.8) | 51 | 8 (15.7) | 6 (11.8) |
| HPV 39/51/56/59/68 | 265 | 36 (13.6) | 24 (9.1) | 91 | 18 (19.8) | 12 (13.2) |
| Coinfection with 16 or 18 | 50 | 8 (16.0) | 6 (12.0) | 12 | 2 (16.7) | 1 (8.3) |
| Any coinfection | 139 | 30 (21.6) | 23 (16.5) | 42 | 4 (9.5) | 3 (7.1) |
CINcervical intraepithelial neoplasiaHPVhuman papillomavirus